Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine
(T4), or Synthroid, is the most commonly prescribed agent for the management of
hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may
have benefits in preventing disease progression over l-thyroxine (T4).